Navigation Links
SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)
Date:11/5/2008

BARCELONA, Spain, November 5 /PRNewswire/ -- SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL(R) (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers). In an Approvable Letter received on April 6, 2006, the FDA requested additional data with respect to chemistry, manufacturing, and controls (CMC).

SALVAT expects the FDA to classify the complete response as a Class 2 resubmission, under which the FDA will seek to complete its review of the resubmission within 180 days from the time of resubmission. SALVAT believes that the response submitted today to the FDA fully addresses the Agency request.

The Approvable Letter did not raise any questions related to efficacy or safety of CETRAXAL(R) Otic Solution.

SALVAT is currently evaluating potential commercial partners in the United States to licensing out CETRAXAL(R) and expects to launch it during the second quarter of 2009, subject to FDA approval.

The NDA for CETRAXAL(R) seeks marketing approval for the treatment of Acute Otitis Externa in pediatric (aged 1 year and older) and adult patients.

About CETRAXAL(R)

CETRAXAL(R) is a Ciprofloxacin 0.2% Otic Solution for the treatment of Acute Otitis Externa. In a phase III clinical trial compared to Neomycin, Polymyxin B sulfates and Hydrocortisone otic solution (NPH), CETRAXAL(R) obtained a clinical cure rate of 93.9% in pediatric patients (vs. 76.0% in the NPH group) and resolved or improved otalgia in 99.2% of the patients. There were no adverse reactions with an incidence higher than 1%. CETRAXAL(R) will be available in sterile, preservative-free single-dose containers which make easy to ensure correct dosing and to place drops into the ear.

About SALVAT

SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. The most advanced NCE is SVT-40776 for the treatment of Overactive Bladder, which has recently finished phase II. In 2007 SALVAT's products were distributed in more than 30 countries all over the world in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments and by emphasizing collaborations regarding its pipeline products.

Contact:

Cristina Viayna,

Business Development & Licensing,

cviayna@salvatbiotech.com ,

Phone: +1-305-774-9727.

http://www.salvatbiotech.com


'/>"/>
SOURCE SALVAT
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
2. Telik Announces Financial Results for 2008 Third Quarter
3. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
4. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
5. Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan
6. Environmental Tectonics Corporation Announces Staff Addition to Its BioMedical Systems Division
7. Misonix Announces New Distribution Agreement for The Netherlands
8. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
11. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):